Humana Inc. (NYSE:HUM – Get Free Report) announced a quarterly dividend on Thursday, February 20th, RTT News reports. Shareholders of record on Friday, March 28th will be given a dividend of 0.885 per share by the insurance provider on Friday, April 25th. This represents a $3.54 annualized dividend and a yield of 1.38%. The ex-dividend date of this dividend is Friday, March 28th.
Humana has raised its dividend payment by an average of 8.1% annually over the last three years. Humana has a payout ratio of 25.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Humana to earn $13.13 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 27.0%.
Humana Trading Down 5.7 %
Shares of Humana stock opened at $255.77 on Friday. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a 50-day simple moving average of $269.41 and a two-hundred day simple moving average of $290.45. The company has a market cap of $30.80 billion, a P/E ratio of 25.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56.
Insider Activity at Humana
In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by insiders.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Barclays upped their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Finally, TD Cowen upped their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $285.68.
Get Our Latest Analysis on HUM
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
- Five stocks we like better than Humana
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 02/17 – 02/21
- Election Stocks: How Elections Affect the Stock Market
- SolarEdge: A Surprising Bright Spot in a Troubled Solar Industry?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.